What question did this study set out to answer?

To evaluate the efficacy and safety of a selinexor-melphalan conditioning regimen in patients with multiple myeloma.

December 8, 2025BloodOpen Access

A novel conditioning regimen combining selinexor with melphalan Improves Survival in Patients with multiple myeloma:a prospective study

View Full Paper

Ask AI

Bookmark

Authors

Prospective study shows melphalan with selinexor enhances survival in multiple myeloma, indicating manageable toxicity.

To evaluate the efficacy and safety of a selinexor-melphalan conditioning regimen in patients with multiple myeloma.
Prospective study design involving 32 patients with multiple myeloma
Selinexor and melphalan administered prior to autologous hematopoietic stem cell transplantation
Conditioning dosage adjusted for renal function in one patient with vomiting due to side effects
45% of evaluable patients achieved deeper responses post-transplant
1-year progression-free survival estimated at 90.9%
Minimal residual disease was negative in 56% of patients with pre-transplant residual disease
No grade 4-5 adverse events or transplant-related deaths observed

Ma et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Prospective study shows melphalan with selinexor enhances survival in multiple myeloma, indicating manageable toxicity.

To evaluate the efficacy and safety of a selinexor-melphalan conditioning regimen in patients with multiple myeloma.
Prospective study design involving 32 patients with multiple myeloma
Selinexor and melphalan administered prior to autologous hematopoietic stem cell transplantation
Conditioning dosage adjusted for renal function in one patient with vomiting due to side effects
45% of evaluable patients achieved deeper responses post-transplant
1-year progression-free survival estimated at 90.9%
Minimal residual disease was negative in 56% of patients with pre-transplant residual disease
No grade 4-5 adverse events or transplant-related deaths observed

Ma et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark